Kidney Stone Formation: A Multifaceted Perspective on Pathogenesis, Diagnostics, and Emerging Therapeutic Strategies

Abstract

Kidney stone disease, or nephrolithiasis, represents a significant global health burden characterized by high prevalence, recurrence rates, and associated morbidities. While traditionally viewed as a primarily metabolic disorder, contemporary research increasingly emphasizes the complex interplay of genetic predisposition, dietary influences, gut microbiome composition, and systemic inflammatory responses in the pathogenesis of kidney stone formation. This research report provides a comprehensive overview of the current understanding of kidney stone disease, encompassing the diverse compositions of kidney stones and their underlying etiologies. We delve into the latest advancements in diagnostic modalities, including cutting-edge imaging techniques and sophisticated metabolic profiling, and critically evaluate established and emerging therapeutic strategies, with a particular focus on preventative measures and personalized treatment approaches. Furthermore, we discuss the potential of novel therapeutic targets identified through genomic and proteomic studies and highlight promising research directions aimed at revolutionizing the management of kidney stone disease. Finally, we offer a perspective on the existing challenges and knowledge gaps in the field, underscoring the imperative for collaborative and interdisciplinary research to improve patient outcomes and alleviate the burden of this debilitating condition.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Nephrolithiasis, the formation of stones within the kidneys, is a prevalent and painful condition affecting a significant proportion of the global population. Its incidence has steadily risen in recent decades, reflecting changes in dietary habits, lifestyle factors, and potentially environmental exposures [1]. The formation of kidney stones is a complex process involving supersaturation of urine with various mineral salts, nucleation, crystal growth, and aggregation, ultimately leading to the formation of macroscopic calculi [2]. The composition of kidney stones varies widely, with calcium oxalate being the most common type, followed by calcium phosphate, uric acid, struvite (magnesium ammonium phosphate), and cystine stones [3]. Understanding the specific composition of kidney stones is crucial for guiding diagnostic evaluation and tailoring treatment strategies.

Traditionally, risk factors for kidney stone formation have been attributed to metabolic abnormalities such as hypercalciuria, hyperoxaluria, hypocitraturia, and hyperuricosuria. However, emerging evidence suggests that genetic predisposition, gut microbiome dysbiosis, systemic inflammation, and alterations in renal tubular transport play critical roles in stone pathogenesis [4]. Furthermore, the geographical distribution of kidney stone disease varies significantly, reflecting differences in dietary patterns, climate, and genetic background. This heterogeneity underscores the need for a comprehensive and individualized approach to the diagnosis and management of kidney stone disease.

This research report aims to provide a multifaceted perspective on kidney stone formation, encompassing the intricate interplay of genetic, environmental, and metabolic factors. We will review the latest advances in diagnostic techniques, including novel imaging modalities and sophisticated metabolic profiling tools. Furthermore, we will critically evaluate established and emerging therapeutic strategies, with a particular emphasis on preventative measures and personalized treatment approaches. By synthesizing current knowledge and highlighting promising research directions, this report seeks to contribute to a deeper understanding of kidney stone disease and pave the way for more effective prevention and management strategies.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Pathogenesis of Kidney Stone Formation

The formation of kidney stones is a complex and multifactorial process involving a delicate balance between factors that promote crystal formation and those that inhibit it. This intricate interplay is influenced by a range of intrinsic and extrinsic factors, including urine composition, pH, flow rate, and the presence of promoters and inhibitors of crystallization [5].

2.1. Supersaturation and Nucleation

The initial step in kidney stone formation is the supersaturation of urine with respect to specific mineral salts, such as calcium oxalate, calcium phosphate, uric acid, or struvite. Supersaturation refers to a state in which the concentration of a solute exceeds its solubility limit in a given solvent [6]. When the urine becomes sufficiently supersaturated, spontaneous nucleation can occur, leading to the formation of tiny crystals. The rate of nucleation is influenced by the degree of supersaturation, the presence of foreign particles that can act as nucleation sites, and the temperature of the urine [7].

2.2. Crystal Growth and Aggregation

Once crystals have formed, they can grow in size by attracting additional ions from the supersaturated solution. Crystal growth is influenced by factors such as the degree of supersaturation, the presence of crystal growth inhibitors, and the surface properties of the crystals themselves [8]. In addition to crystal growth, crystals can also aggregate, forming larger clusters that are more likely to be retained within the renal tubules. Crystal aggregation is promoted by factors such as high ionic strength, reduced urine flow rate, and the presence of specific aggregating agents [9].

2.3. The Role of Inhibitors and Promoters

The formation of kidney stones is not solely determined by the degree of supersaturation. The presence of inhibitors and promoters of crystallization also plays a critical role. Inhibitors of crystallization, such as citrate, magnesium, and Tamm-Horsfall protein, can bind to crystal surfaces and prevent their growth and aggregation [10]. Conversely, promoters of crystallization, such as oxalate, calcium, and uric acid, can enhance crystal formation and growth [11]. The balance between inhibitors and promoters determines the overall propensity for kidney stone formation.

2.4. Genetic Predisposition and Metabolic Disorders

Genetic factors play a significant role in the susceptibility to kidney stone formation. Several genes have been implicated in the pathogenesis of nephrolithiasis, including genes involved in calcium homeostasis, oxalate metabolism, and renal tubular transport [12]. For example, mutations in the SLC26A6 gene, which encodes an oxalate transporter in the kidney, have been associated with increased urinary oxalate excretion and an increased risk of calcium oxalate stones [13]. Similarly, mutations in the CASR gene, which encodes the calcium-sensing receptor, have been linked to familial hypocalciuric hypercalcemia, a condition characterized by elevated serum calcium levels and a reduced risk of calcium stones [14].

In addition to genetic predisposition, metabolic disorders such as hyperparathyroidism, distal renal tubular acidosis, and cystinuria can significantly increase the risk of kidney stone formation. These disorders disrupt normal metabolic pathways and lead to abnormalities in urine composition, promoting crystal formation and growth [15].

2.5. The Gut Microbiome and Kidney Stone Disease

Emerging evidence suggests that the gut microbiome plays a crucial role in the pathogenesis of kidney stone disease. The gut microbiome is a complex community of microorganisms that reside in the gastrointestinal tract and perform a variety of functions, including nutrient metabolism, immune regulation, and protection against pathogens [16]. Certain gut bacteria, such as Oxalobacter formigenes, can degrade oxalate in the gut, reducing the amount of oxalate that is absorbed and excreted in the urine [17]. Conversely, other gut bacteria can produce oxalate, increasing the risk of calcium oxalate stones [18]. Alterations in the gut microbiome composition, known as dysbiosis, have been linked to increased urinary oxalate excretion and an increased risk of calcium oxalate stones [19]. The mechanisms underlying the gut-kidney axis in kidney stone disease are complex and involve interactions between gut bacteria, host immunity, and renal physiology. Further research is needed to fully elucidate the role of the gut microbiome in kidney stone pathogenesis and to develop targeted interventions to modulate the gut microbiome for the prevention and treatment of kidney stone disease.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Diagnostic Techniques

A comprehensive diagnostic evaluation is essential for patients with kidney stone disease to determine the underlying etiology, assess the severity of the condition, and guide treatment decisions. The diagnostic approach typically involves a combination of imaging studies, urine analysis, and metabolic profiling [20].

3.1. Imaging Studies

Imaging studies are crucial for detecting kidney stones, determining their size and location, and assessing the presence of any associated complications, such as hydronephrosis. Several imaging modalities are available for evaluating patients with kidney stone disease, including:

• Non-contrast computed tomography (NCCT): NCCT is the gold standard for detecting kidney stones due to its high sensitivity and specificity [21]. NCCT can detect stones of all compositions, including radiolucent uric acid stones, and can accurately determine their size and location. However, NCCT involves exposure to ionizing radiation, which is a concern, particularly in children and pregnant women.
• Ultrasound: Ultrasound is a non-invasive and radiation-free imaging modality that can be used to detect kidney stones. Ultrasound is particularly useful for detecting stones in the renal pelvis and proximal ureter, but its sensitivity is lower than that of NCCT, especially for small stones or stones located in the distal ureter [22].
• Intravenous pyelogram (IVP): IVP is a radiographic imaging technique that involves injecting a contrast agent into the bloodstream and taking a series of X-ray images of the kidneys, ureters, and bladder. IVP can provide information about the anatomy of the urinary tract and the presence of any obstructions, but it is less sensitive than NCCT for detecting kidney stones and involves exposure to ionizing radiation and contrast agents [23].
• Dual-energy CT (DECT): DECT is an advanced CT technique that uses two different X-ray energies to differentiate between different types of kidney stones. DECT can be used to identify uric acid stones, which are radiolucent on conventional CT, and can potentially guide treatment decisions [24].

3.2. Urine Analysis

Urine analysis is an essential component of the diagnostic evaluation for kidney stone disease. Urine analysis can provide information about the concentration of various solutes in the urine, the pH of the urine, and the presence of any crystals, bacteria, or blood. Key urine parameters that are assessed in patients with kidney stone disease include:

• 24-hour urine collection: A 24-hour urine collection is used to measure the excretion of various solutes in the urine, including calcium, oxalate, uric acid, citrate, phosphate, sodium, and creatinine. The 24-hour urine collection is crucial for identifying metabolic abnormalities that may be contributing to kidney stone formation [25].
• Urinalysis: A urinalysis is used to assess the pH of the urine, the presence of any crystals, bacteria, or blood, and the specific gravity of the urine. The urinalysis can provide clues about the composition of the kidney stones and the presence of any urinary tract infections [26].
• Urine culture: A urine culture is used to detect the presence of any bacteria in the urine. A urine culture is particularly important in patients with struvite stones, which are often associated with urinary tract infections caused by urease-producing bacteria [27].

3.3. Metabolic Profiling

Metabolic profiling, also known as metabolomics, is a powerful technique that can be used to identify and quantify a wide range of metabolites in biological samples, such as urine and serum. Metabolic profiling can provide a comprehensive snapshot of an individual’s metabolic state and can be used to identify novel biomarkers for kidney stone disease [28]. Several studies have used metabolic profiling to identify potential biomarkers for predicting kidney stone recurrence, differentiating between different types of kidney stones, and monitoring the response to treatment [29]. While metabolomics holds great promise, the technical complexity of its measurement and analysis has slowed its adoption as a standard clinical tool.

3.4. Stone Analysis

The gold standard for determining the composition of kidney stones is stone analysis. Stone analysis involves analyzing the chemical composition of the stone using various techniques, such as X-ray diffraction, infrared spectroscopy, or chemical analysis [30]. Stone analysis is crucial for guiding treatment decisions, particularly in patients with recurrent kidney stones. Knowing the stone composition allows clinicians to tailor preventative strategies to target the specific metabolic abnormalities that are contributing to stone formation.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Therapeutic Strategies

The management of kidney stone disease involves a combination of acute treatment for symptomatic stones and preventative measures to reduce the risk of recurrence. The specific therapeutic approach depends on the size, location, and composition of the stone, as well as the presence of any associated complications and the patient’s overall health [31].

4.1. Acute Treatment

Acute treatment for symptomatic kidney stones focuses on relieving pain, facilitating stone passage, and preventing complications such as infection and kidney damage. Several treatment options are available, including:

• Pain management: Pain is a common symptom of kidney stone disease and is typically managed with analgesics, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or opioids. Alpha-blockers can also be used to relax the ureteral muscles and facilitate stone passage [32].
• Medical expulsive therapy (MET): MET involves the use of medications, such as alpha-blockers or calcium channel blockers, to relax the ureteral muscles and facilitate stone passage. MET is typically used for small to moderate-sized stones that are likely to pass spontaneously [33].
• Extracorporeal shock wave lithotripsy (ESWL): ESWL is a non-invasive procedure that uses shock waves to break up kidney stones into smaller fragments that can be passed more easily. ESWL is typically used for stones that are located in the kidney or upper ureter and are less than 2 cm in size [34].
• Ureteroscopy: Ureteroscopy is a minimally invasive procedure that involves inserting a small, flexible scope into the ureter to visualize and remove the stone. Ureteroscopy can be used to treat stones located anywhere in the ureter or kidney and is particularly useful for stones that are too large or too hard to be treated with ESWL [35].
• Percutaneous nephrolithotomy (PCNL): PCNL is a surgical procedure that involves making a small incision in the back and inserting a scope into the kidney to remove the stone. PCNL is typically used for large or complex stones that cannot be treated with ESWL or ureteroscopy [36].

4.2. Preventative Measures

Preventative measures are crucial for reducing the risk of kidney stone recurrence. The specific preventative strategies depend on the underlying etiology of the stone and may include:

• Dietary modifications: Dietary modifications are a cornerstone of kidney stone prevention. General recommendations include increasing fluid intake, reducing sodium intake, limiting animal protein intake, and avoiding oxalate-rich foods [37]. Specific dietary recommendations depend on the composition of the stone. For example, patients with calcium oxalate stones are often advised to limit their intake of oxalate-rich foods, such as spinach, rhubarb, and nuts [38].
• Medications: Several medications can be used to prevent kidney stone formation. Thiazide diuretics can be used to reduce urinary calcium excretion in patients with hypercalciuria [39]. Potassium citrate can be used to increase urinary citrate excretion and raise urine pH in patients with hypocitraturia or uric acid stones [40]. Allopurinol can be used to reduce uric acid production in patients with hyperuricosuria and uric acid stones [41].
• Fluid intake: Increasing fluid intake is a simple but effective way to prevent kidney stone formation. Adequate fluid intake helps to dilute the urine and reduce the concentration of mineral salts, decreasing the risk of supersaturation and crystal formation. Patients with kidney stone disease are generally advised to drink enough fluids to produce at least 2.5 liters of urine per day [42].
• Lifestyle Modifications: Weight loss and regular exercise can also help to prevent kidney stone formation by improving metabolic health and reducing the risk of obesity-related risk factors, such as insulin resistance and hyperuricosuria [43].

4.3 Emerging Therapeutic Strategies

Novel therapeutic strategies for kidney stone disease are constantly being developed and investigated. Some promising areas of research include:

• Targeting the gut microbiome: Modulation of the gut microbiome holds promise for preventing calcium oxalate stones. Strategies include probiotic supplementation with Oxalobacter formigenes or other oxalate-degrading bacteria, as well as dietary interventions to promote a healthy gut microbiome [44].
• Nanotechnology-based therapies: Nanoparticles can be used to deliver drugs directly to the site of stone formation or to inhibit crystal growth. Nanoparticles can also be used to develop novel diagnostic tools for early detection of kidney stones [45].
• Gene therapy: Gene therapy holds potential for correcting genetic defects that contribute to kidney stone formation, such as mutations in genes involved in oxalate metabolism or renal tubular transport [46].
• Personalized medicine: Personalized medicine approaches, which tailor treatment strategies to an individual’s specific genetic and metabolic profile, are becoming increasingly important in the management of kidney stone disease. Personalized medicine can help to optimize treatment outcomes and reduce the risk of recurrence [47].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Kidney Stones in Pediatric Patients

While kidney stones are more common in adults, they can also occur in children. The incidence of kidney stones in children has been increasing in recent decades, likely due to changes in dietary habits, lifestyle factors, and increased awareness [48]. The etiology of kidney stones in children differs from that in adults, with genetic and metabolic disorders playing a more prominent role. Common causes of kidney stones in children include hypercalciuria, hyperoxaluria, cystinuria, and distal renal tubular acidosis [49].

The diagnosis and management of kidney stones in children require a tailored approach, taking into account the unique physiological and developmental characteristics of this population. Imaging studies should be used judiciously to minimize radiation exposure, and treatment strategies should be individualized based on the size, location, and composition of the stone, as well as the child’s overall health [50]. Preventative measures, such as dietary modifications and medications, are crucial for reducing the risk of recurrence in children with kidney stone disease [51].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Challenges and Future Directions

Despite significant advances in our understanding of kidney stone disease, several challenges remain. These include:

• The complexity of stone pathogenesis: Kidney stone formation is a complex process involving multiple factors, making it difficult to fully understand the underlying mechanisms and develop effective prevention strategies.
• The heterogeneity of kidney stone disease: Kidney stone disease is a heterogeneous condition, with different types of stones and different underlying etiologies. This heterogeneity makes it challenging to develop universal prevention and treatment strategies.
• The limitations of current diagnostic techniques: Current diagnostic techniques have limitations in terms of sensitivity, specificity, and invasiveness. There is a need for more accurate and non-invasive diagnostic tools for early detection and characterization of kidney stones.
• The lack of effective preventative therapies: While several preventative therapies are available, they are not always effective in preventing kidney stone recurrence. There is a need for more effective and targeted preventative therapies.

Future research directions in kidney stone disease should focus on:

• Elucidating the role of the gut microbiome in kidney stone pathogenesis: Further research is needed to fully understand the role of the gut microbiome in kidney stone disease and to develop targeted interventions to modulate the gut microbiome for prevention and treatment.
• Developing novel diagnostic tools for early detection and characterization of kidney stones: There is a need for more accurate and non-invasive diagnostic tools for early detection and characterization of kidney stones. These tools should be able to differentiate between different types of stones and predict the risk of recurrence.
• Developing personalized medicine approaches for kidney stone prevention and treatment: Personalized medicine approaches, which tailor treatment strategies to an individual’s specific genetic and metabolic profile, hold great promise for improving outcomes in kidney stone disease.
• Identifying novel therapeutic targets for kidney stone prevention and treatment: There is a need to identify novel therapeutic targets for kidney stone prevention and treatment. These targets should be based on a better understanding of the underlying mechanisms of kidney stone formation.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Conclusion

Kidney stone disease is a complex and multifactorial condition that poses a significant global health burden. While significant progress has been made in understanding the pathogenesis, diagnosis, and management of kidney stones, several challenges remain. Future research efforts should focus on elucidating the role of the gut microbiome, developing novel diagnostic tools, and implementing personalized medicine approaches. By addressing these challenges, we can improve patient outcomes and alleviate the burden of this debilitating condition.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

[1] Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010;12(2-3):e86-e96.
[2] Khan SR, Pearle MS, Robertson WG, Gambaro G, Canales BK, Doizi S, Traxer O, Tiselius HG. Kidney stones. Nat Rev Dis Primers. 2016 Feb 25;2:16008.
[3] Coe FL, Evan AP, Worcester EM. Kidney stone disease. J Clin Invest. 2005 Oct;115(10):2598-608.
[4] Lieske JC, Goldfarb DS. Dietary, genetic, and other modifiable risk factors for kidney stones. Clin J Am Soc Nephrol. 2011;6(9):2216-2223.
[5] Kumar V, Yadav AK, Banerjee BD, Rastogi S. Pathophysiology of renal stone formation. Indian J Nephrol. 2013 Jul;23(4):254-61.
[6] Tiselius HG. Solution chemistry of supersaturation and crystal growth in calcium oxalate stone formation. Urol Res. 1991;19(4):255-64.
[7] Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med. 1992 Jun 4;326(26):1779-88.
[8] Worcester EM, Coe FL. Nephrolithiasis. Prim Care. 2008 Sep;35(3):469-92, vii.
[9] Hess B, Kok DJ. Nucleation, growth and aggregation of calcium oxalate crystals. J Cryst Growth. 1992 Jan 1;119(1-2):175-81.
[10] Worcester EM, Birdwell CR, Coe FL. Identification of proteins that inhibit calcium oxalate crystal growth in human urine. Am J Physiol. 1988 Aug;255(2 Pt 2):F225-31.
[11] Khan SR. Crystal-matrix interaction in calcium oxalate urolithiasis. World J Urol. 1997 Aug;15(5):247-55.
[12] Reed B, Stapleton C, Tantisattayakul G, et al. Genetic contributions to nephrolithiasis. Am J Kidney Dis. 2014;64(4):613-622.
[13] Jiang Z, Asplin JR, Evan AP, Goldfarb DS, Levine BS, Coe FL. Mice lacking anion transporter Slc26a6 are hyperoxaluric and susceptible to calcium oxalate nephrolithiasis. Am J Physiol Renal Physiol. 2006 Dec;291(6):F1257-64.
[14] Vargas-Poussou R, Baron S, Alberti C, et al. Evaluation of the calcium-sensing receptor gene in familial hypocalciuric hypercalcemia. J Am Soc Nephrol. 1998 Dec;9(12):2286-94.
[15] Moe OW. Kidney stones: pathophysiology and medical management. Lancet. 2006 Mar 18;367(9507):333-44.
[16] Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, Gordon JI, Relman DA, Fraser-Liggett CM, Nelson KE. Metagenomic analysis of the human distal gut microbiome. Science. 2006 Jun 2;312(5778):1355-9.
[17] Allison MJ, Dawson KA, Mayberry WR, Foss JG. Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobic bacteria from the rumen. Arch Microbiol. 1985 Oct;141(1):1-7.
[18] Siener R, Metzner C, Hesse A. Influence of a probiotic mixture on urinary oxalate excretion in healthy volunteers. Eur J Clin Nutr. 2013 Jun;67(6):591-5.
[19] Ticinesi A, Nouvenne A, Meschi T, Guerra A, Allegri F, Lippi G, Lauretani F, Maggio M. Gut microbiota and kidney stone disease: a systematic review. Urol Int. 2018;100(4):317-326.
[20] Pearle MS, Goldfarb DS, Assimos DG, Curhan GC, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TMT, White JR; American Urological Association. Medical management of kidney stones: AUA guideline. J Urol. 2014 Aug;192(2):316-24.
[21] Smith RC, Verga M, McCarthy S, Rosenfield AT. Diagnosis of acute flank pain: comparison of unenhanced helical CT and intravenous urography. AJR Am J Roentgenol. 1996 Sep;167(3):789-93.
[22] Shea BJ, Berlin SJ, Jarrett TW. The role of ultrasound in the diagnosis and management of urolithiasis. Urol Clin North Am. 2007 Aug;34(3):397-408, viii.
[23] Dyer RB, Chen MYM, Zagoria RJ. Classic signs in uroradiology. Radiographics. 2004 Nov-Dec;24 Suppl 1:S247-80.
[24] Nakada SY, Hoff DG, Attai S, Heidenreich A, Williams JC Jr. Determination of stone composition by noncontrast spiral computed tomography in vitro. Urology. 2000 Sep 1;56(3):369-72.
[25] Pak CY. Medical management of nephrolithiasis–state of the art. J Urol. 1998 Sep;160(3 Pt 1):523-33.
[26] Fogazzi GB, Garigali G, Zocchi L. The diagnostic value of urine microscopy. J Nephrol. 2007 Jan-Feb;20(1):5-13.
[27] Griffith DP. Struvite stones. Kidney Int. 1978 Jan;13(5):372-82.
[28] Heilberg IP, Teixeira SR, Park SK, Ribeiro CG, Evangelista JS, Lobo JC, de Almeida EC, Machado D, Barros ER. Metabolic profiling of kidney stone formers with calcium oxalate stones. Kidney Int. 2010 May;77(9):827-35.
[29] Mandal R, Wishart DS. Recent advances in applications of metabolomics in nephrology. Clin J Am Soc Nephrol. 2014;9(3):563-575.
[30] Hesse A, Heimbach D. Procedures for stone analysis. Urol Res. 1999 Aug;27(5):357-61.
[31] Moe OW. Kidney stones: medical management. Clin J Am Soc Nephrol. 2006;1(1):219-227.
[32] Pickard R, Starr M, Neal DE, et al. Alpha-blockers and calcium channel blockers for treatment of ureteric colic: a single-blind, randomised, placebo-controlled trial. BMJ. 2015;351:h6740.
[33] Preminger GM, Tiselius HG, Assimos DG, Alken P, Buck AC, Gallucci M, Knoll T, Osther PJ, Pearle MS, Rodgers A, Tan YH. EAU guidelines on urolithiasis. Eur Urol. 2007 Mar;52(3):528-31.
[34] Chaussy C, Schmiedt E, Jocham D, Brendel W, Forssmann B, Walther V. First clinical experience with extracorporeally induced destruction of kidney stones by shock waves. J Urol. 1982 Oct;127(3):417-20.
[35] Monga M, Landman J, Mues AC, et al. Ureteroscopy for ureteral calculi: predictors of success and failure. Urology. 2003 Oct;62(4):608-12.
[36] Segura JW, Preminger GM, Assimos DG, Dretler SP, Kahn RI, Lingeman JE, Macaluso JN Jr, McCullough DL, et al. Nephrolithiasis clinical guidelines panel summary report on the management of staghorn calculi. The American Urological Association Nephrolithiasis Clinical Guidelines Panel. J Urol. 1994 Dec;152(6 Pt 1):2281-8.
[37] Curhan GC. Dietary protein and potassium as determinants of metabolic risk factors for kidney stones. J Am Soc Nephrol. 2006 Sep;17(9):2533-40.
[38] Taylor EN, Curhan GC. Dietary oxalate and the risk of incident kidney stones. J Am Soc Nephrol. 2007 Sep;18(7):2198-204.
[39] Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Am Soc Nephrol. 1997 Jun;8(6):841-5.
[40] Nicar MJ, Hill W. Long-term efficacy and safety of potassium citrate therapy in idiopathic hypocitraturic calcium oxalate nephrolithiasis. J Urol. 1993 Jul;150(2 Pt 1):386-9.
[41] Pillay I, Swart R, Veller MG. Allopurinol in the management of uric acid calculi: experience at the Johannesburg General Hospital. S Afr Med J. 1980 Sep 27;58(13):531-4.
[42] Borghi L, Meschi T, Amato A, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol. 1996 Mar;155(3):839-43.
[43] Liese AD, Houser RF, Gray NM, Ma L, Porterfield DS, Topazian HM, Freedman BI. Weight, weight change and risk of kidney stones: the Insulin Resistance Atherosclerosis Study (IRAS). Int J Obes (Lond). 2011 Nov;35(11):1397-403.
[44] Lieske JC, Goldfarb DS, De Simone C, Regnier C. Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int. 2005 Jul;68(3):1244-9.
[45] Desai MP, Labhasetwar V. Nanoparticle-mediated drug delivery for urologic diseases. Adv Drug Deliv Rev. 2014 Oct;76:93-107.
[46] Holmes RP, Kennedy M. Estimation of the oxalate content of foods and daily oxalate intake. Kidney Int. 2000 Dec;59(3):702-10.
[47] Hoppe B, Kemper MJ. Diagnostic examination of the child with nephrolithiasis or nephrocalcinosis. Pediatr Nephrol. 2010 Aug;25(8):1415-25.
[48] Sas DJ, de Finkelstein MH, Worley S, Toledo K, Moorehead P. Increasing incidence of kidney stones in children. J Pediatr. 2010 May;157(1):132-7.
[49] Ferraro PM, Curhan GC, Gambaro G, Taylor EN. Total, animal, and vegetable protein intake and risk of kidney stones. J Am Soc Nephrol. 2006 Jan;17(1):234-40.
[50] Smoyer WE, Tasian GE. Clinical practice. Kidney stones in children. N Engl J Med. 2016 Sep 15;375(11):1062-70.
[51] Stapleton C, Reed B, Tantisattayakul G, Norman J, Tonto-Agosti P, Schwaderer A, Baum MA. Pediatric kidney stone recurrences. Pediatr Nephrol. 2014 Jan;29(1):121-9.